Navigation Links
Transient receptor potential channel A1 may contribute to hyperalgesia
Date:12/23/2013

Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia. However, there is no direct evidence that activation of transient receptor potential channel A1 contributes to neuropeptide release from primary afferent neurons. A recent study by Yi Dai and team from Hyogo College of Medicine in Japan demonstrated for the first time that allyl isothiocyanate (AITC; also known as mustard oil) activates transient receptor potential channel A1, resulting in calcitonin gene-related peptide release from the cultured rat dorsal root ganglion neurons. Knockdown of transient receptor potential channel A1 with an antisense oligodeoxynucleotide prevented calcitonin gene-related peptide release by allyl isothiocyanate application in cultured dorsal root ganglion neurons. Thus, the researchers concluded that transient receptor potential channel A1 activation caused calcitonin gene-related peptide release in sensory neurons. These findings were published in the Neural Regeneration Research (Vol. 8, No. 32, 2013).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related biology news :

1. Stanford and Google team up to simulate key drug receptor
2. Extensive variability in olfactory receptors influences human odor perception
3. Researchers use nanoscale patches to sensitize targeted cell receptors
4. New book on Signaling by Receptor Tyrosine Kinases by Cold Spring Harbor Laboratory Press
5. Dysfunctional chemokine receptor promotes candidiasis
6. Baculovirus-recognizing human cell receptor identified for the first time
7. Blocking overactive receptor in Alzheimers recovers memory loss and more
8. OHSU scientists advance understanding of brain receptor; may help fight neurological disorders
9. Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
10. Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
11. Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transient receptor potential channel A1 may contribute to hyperalgesia
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
Breaking Biology Technology: